NewsNational NewsScripps News


OxyContin marketer, opioid maker agree to $500M in settlements

Publicis Health will pay $350 million to avoid going to trial over claims that it contributed to the opioid epidemic.
OxyContin marketer, opioid maker agree to $500M in settlements
Posted at 9:01 PM, Feb 01, 2024

An advertising agency that helped develop marketing campaigns for OxyContin and other prescription painkillers and a drugmaker announced separate agreements Thursday worth a total of $500 million to avoid going to trial on claims that they bore some responsibility for the nation's opioid crisis.

Publicis Health, part of the Paris-based media conglomerate Publicis Groupe, agreed to pay $350 million, part of which will flow to every state in the next two months, and most of which will be used to fight the overdose epidemic.

Hikma Pharmaceuticals agreed to pay $115 million in cash and provide $35 million worth of an overdose reversal drug to state, local and Native American tribal governments.

Publicis is the first advertising company to reach a major settlement over the toll of opioids in the U.S. It had faced a lawsuit in Massachusetts but settled with most states before they made court claims against it.

The office of New York Attorney General Letitia James, who led negotiations with the company, said Publicis worked with OxyContin maker Purdue Pharma from 2010-2019, helping campaigns for OxyContin and other prescription opioids, Butrans and Hysingla.

James' office said the materials played up the abuse-deterrent properties of OxyContin and promoted increasing patients' doses. While the formulation made it harder to break down the drug for users to get a faster high, it did not make the pills any less addictive.

Washington Attorney General Bob Ferguson said the company provided physicians with digital recorders so Publicis and Purdue could analyze conversations that the prescribers had with patients about taking opioids.

As part of the settlement, Publicis agreed to release internal documents detailing its work for Purdue and other companies that made opioids.

The company said in a statement that the settlement is not an admission of wrongdoing and noted that most of the work subject to the settlement was done by Rosetta, a company owned by Publicis that closed 10 years ago.

"Rosetta's role was limited to performing many of the standard advertising services that agencies provide to their clients, for products that are to this day prescribed to patients, covered by major private insurers, Medicare, and authorized by State Pharmacy Boards," Publicis said.

The company also reaffirmed its policy of not taking new work on opioid-related products.

Publicis added that the company's insurers are reimbursing it for $130 million and that $7 million of the settlement amount will be used for states' legal fees.

SEE MORE: This experimental painkiller could be alternative to addictive opioids

London-based Hikma also said its settlement is not an admission of wrongdoing.

Drugmakers, wholesalers, pharmacies, at least one consulting company and a health data firm have agreed to settlements over opioids with U.S. federal, state and local governments totaling more than $50 billion.

One of the largest individual proposed settlements is between state and local governments and Connecticut-based Purdue Pharma. As part of the deal, members of the Sackler family who own the company would contribute up to $6 billion, plus give up ownership. The U.S. Supreme Court is weighing whether it's appropriate to shield family members from civil lawsuits as part of the deal.

The opioid crisis has killed hundreds of thousands of Americans in three waves.

The first began after OxyContin hit the market in 1996 and was linked mostly to prescription opioids, many of them generics. By about 2010, as there were crackdowns on over-prescribing and black-market pills, heroin deaths increased dramatically. Most recently, opioids have been linked to more than 80,000 deaths a year, more than ever before. Most involve illicitly produced fentanyl and other potent lab-produced drugs.

Trending stories at